Development of cladribine treatment in multiple sclerosis

Abstract

Cladribine is a new type of drug with properties of selective lymphocyte suppression that appear to favorably alter the clinical course of progressive multiple sclerosis (MS). The history of the development of cladribine treatment in chronic progressive MS is discussed, and the application of cladribine treatment to progressive multiple sclerosis in a double-blind, placebo crossover study is reviewed. Cladribine selectively targets both resting and dividing lymphocytes and may be able to destroy the activated lymphocytes that induce CNS demyelination, thus producing stabilization or improvement in chronic MS. Although the role of cladribine has not yet been fully defined, additional studies are underway to evaluate the efficacy and safety of cladribine in both progressive MS and relapsing-remitting MS.

Keywords

multiple sclerosis cladribine immunosuppression

Get full access to this article

View all access options for this article.

References

1 Beutler E . (1992) Cladribine (2-chlorodeoxyadenosine). Lancet 340: 952–956.

2 Beutler E . (1994) New chemotherapeutic agent: 2-chlorodeoxyadenosine. Semin Hematol 31: 40–45.

3 Beutler E et al. (1994) Marrow suppression produced by repeated doses of cladribine. Acta Haematol 91: 10–15.

4 Beutler E et al. (1991) 2-Chlorodeoxyadenosine (2-CdA): A potent chemotherapeutic and immunosuppressive nucleotide. Leuk Lymphoma 5: 1–8.

5 Beutler E et al. (1996) The treatment of chronic progressive multiple sclerosis with cladribine. Proc Natl Acad Sci USA 93: 1716–1720.

6 Carson DA et al. (1979) Biochemical basis for the enhanced toxicity of deoxyribonucleosides toward malignant human T cell lines. Proc Natl Acad Sci USA 76: 2430–2433.

7 Carson DA , Kaye J , Seegmiller JE . (1977) Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside Phosphorylase deficiency: Possible role of nucleoside kinase(s). Proc Natl Acad Sci USA 74: 5677–5681.

8 Carson DA , Seto S , Wasson DB , Carrera CJ . (1986) DNA strand breaks, NAD metabolism, and programmed cell death. Exp Cell Res 164: 273–281.

9 Carson DA , Wasson DB , Beutler E . (1984) Antileukemic and immunosuppressive activity of 2-chloro-2′-deoxyadenosine. Proc Natl Acad Sci USA 81: 2232–2236.

10.

10 Carson DA et al. (1980) Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo. Proc Natl Acad Sci USA 77: 6865–6869.

11.

11 Carson DA et al. (1982) A potent new anti-lymphocyte agent: 2-chlorodeoxyadenosine. Blood 60 (Suppl 1): 161. (Abstract)

12.

12 Carson DA , Wasson DB , Taetle R , Yu A . (1983) Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood 62: 737–743.

13.

13 Giblett ER et al. (1972) Adenosine deaminase deficiency in two patients with severely impaired cellular immunity. Lancet 2: 1067–1069.

14.

14 Grieb P et al. (1994) Cladribine treatment of multiple sclerosis. Lancet 344: 538.

15.

15 Liliemark J et al. (1992) On the bioavailability of oral and subcutaneous 2-chloro-2′-deoxyadenosine in humans: Alternative routes of administration. J Clin Oncol 10: 1514–1518.

16.

16 Piro LD , Carrera CJ , Carson DA , Beutler E . (1990) Lasting remissions in hairy cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 322: 1117–1121.

17.

17 Piro LD et al. (1992) Prolonged complete remissions following 2-chlorodeoxyadenosine (2-CdA) in hairy cell leukemia (HCL). Proc Am Soc Clin Oncol 11: 259. (Abstract)

18.

18 Saven A et al. (1991) 2-Chlorodeoxyadenosine treatment of refractory chronic lymphocytic leukemia. Leuk Lymphoma 5 (Suppl): 133–138.

19.

19 Saven A et al. (1992) 2-Chlorodeoxyadenosine: An active agent in the treatment of cutaneous T-cell lymphoma. Blood 80: 587–592.

20.

20 Saven A , Figueroa ML , Piro LD , Beutler E . (1992) Complete hematological remissions in chronic myelogenous leukemia (CML) following 2-chlorodeoxyadenosine (2-CdA). Proc Am Soc Clin Oncol 11: 261. (Abstract)

21.

21 Saven A et al. (1993) 2-Chlorodeoxyadenosine dose escalation in non-hematologic malignancies. J Clin Oncol 11: 671–678.

22.

22 Sipe JC et al. (1994) Cladribine in treatment of chronic progressive multiple sclerosis. Lancet 344 (No. 8914): 9–13.